Expertise in
3
conditions

Thorsten Bartsch

Arnold Heller Str. 3, 
Kiel, SH, DE 
Expertise in
3
conditions
Arnold Heller Str. 3, 
Kiel, SH, DE 
OverviewLocationsClinical Research

Overview

Thorsten Bartsch practices in Kiel, Germany. Mr. Bartsch is highly rated in 3 conditions, according to our data. His top areas of expertise are Transient Global Amnesia, Memory Loss, Encephalitis, Thrombophlebitis, and Deep Brain Stimulation.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Arnold Heller Str. 3, Kiel, SH 24105, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.
A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: PQ912 Glutaminyl Cyclase Enzyme Inhibitor
Study Phase: Phase 2
View 1 Less Clinical Trial

57 Total Publications

Cognitive Deficits in Anti-LGI1 Encephalitis Are Linked to Immunotherapy-Resistant White Matter Network Changes.
Cognitive Deficits in Anti-LGI1 Encephalitis Are Linked to Immunotherapy-Resistant White Matter Network Changes.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: January 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bartsch's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile